An eight-day joint hearing in cases brought by Allergan alleging infringement of its Botox trade mark, which was due to commence Monday, has been unexpectedly vacated by the court, with barristers and legal teams left in the dark about the reasons.
Chemical giant BASF is appealing an IP Australia ruling that allowed US-based Lubrizol Corporation to amend certain claims of its patent for an improved fuel additive.
Pharmaceutical giant Allergan has streamlined its trade mark case against Self Care Corporation, which makes products marketed as Botox alternatives.
Canadian generic manufacturer Apotex has agreed to drop its lawsuit against India’s Cipla seeking to invalidate its Australian patent for popular nasal spray Dymista.
The Commissioner of Patents will seek to toss a case simultaneously challenging its decisions to accept, grant and certify an innovation patent owned by one of Australia’s biggest building product firms.
The companies that own some of Australia’s largest intellectual property boutiques have agreed to a merger that will create a 349 employee-strong firm that’s a force to be reckoned with in the market for IP services in Asia Pacific.
The Paris-based publisher of Elle Magazine has succeeded in a challenge to a trade mark application by an Australian building supplier for the name of its brand of bathroom fixtures, ‘Ella’.
Generic drug maker Dr Reddy’s Laboratories has reached a settlement with US-based Millennium Pharmaceuticals, agreeing to be restrained from selling a cheap version of cancer drug Velcade in Australia.
Confectionery giant Mars has successfully opposed an application by Kraft Foods for an Australian patent for chocolate that doesn’t melt in the summer months.
The company that manufactures Botox alternatives has denied infringing on Allergan’s Botox trade mark, telling a court Wednesday its use of the word was for comparative purposes only.